Novel epigenetics diagnostic discovery platform from Cambridge Epigenetix identifies robust signatures from liquid biopsy samples
Cambridge, UK, 14 November 2017: Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, has developed a novel and disruptive epigenetic diagnostic discovery platform based on the 5-hydroxymethylcytosine (5hmC) mark. The proprietary platform allows highly accurate signatures to be defined and will form the basis for the Company’s in-house epigenetics-based diagnostic development programmes targeting a number of diseases with unmet need. The initial results of the platform will be presented at the Epigenomics of Common Diseases conference in Hinxton, Cambridge on 16 November 2017.
Epigenetic modifications, particularly 5hmC, provide a powerful, untapped source of biomarkers. CEGX’s patent-protected platform permits detection of highly accurate signatures for various diseases based on the 5hmC mark. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC including earlier disease detection, identification of tissue of origin, robust detection from liquid biopsy samples and identification of new therapeutic targets. CEGX is uniquely placed to capitalise on the potential of this underexploited and fundamental area of molecular medicine and will utilise the discovery platform to develop its internal diagnostic assays.
Dr. Jason Mellad, CEO at CEGX, said: “CEGX has the team and the technology to revolutionise human health and is pioneering the field of epigenetic medicine to deliver improved diagnostic assays. We aim to change the way medicine is practiced by reducing several routine and important diagnostics to a simple blood draw using the power of the 5hmC epigenetic mark. The results thus far provide validation of our platform and promise an exciting future for diagnostic assay development.”
Notes to Editors
Phone: +44 (0)7811 996 942
About Cambridge Epigenetix
Cambridge Epigenetix’s mission is to improve health through the routine measurement of the epigenome. Cambridge Epigenetix utilizes innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com.